- Home
- RNTX vs FENG Comparison
RNTX vs FENG Comparison
Compare RNTX & FENG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- FENG
- Stock Information
- Founded
- RNTX 2001
- FENG 1998
- Country
- RNTX United States
- FENG China
- Employees
- RNTX N/A
- FENG N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- FENG Broadcasting
- Sector
- RNTX Health Care
- FENG Industrials
- Exchange
- RNTX Nasdaq
- FENG Nasdaq
- Market Cap
- RNTX 28.0M
- FENG 26.8M
- IPO Year
- RNTX N/A
- FENG 2011
- Fundamental
- Price
- RNTX $1.15
- FENG $2.66
- Analyst Decision
- RNTX Hold
- FENG
- Analyst Count
- RNTX 1
- FENG 0
- Target Price
- RNTX N/A
- FENG N/A
- AVG Volume (30 Days)
- RNTX 133.3K
- FENG 19.2K
- Earning Date
- RNTX 11-13-2025
- FENG 11-11-2025
- Dividend Yield
- RNTX N/A
- FENG N/A
- EPS Growth
- RNTX N/A
- FENG N/A
- EPS
- RNTX N/A
- FENG N/A
- Revenue
- RNTX N/A
- FENG $101,168,374.00
- Revenue This Year
- RNTX N/A
- FENG N/A
- Revenue Next Year
- RNTX N/A
- FENG N/A
- P/E Ratio
- RNTX N/A
- FENG N/A
- Revenue Growth
- RNTX N/A
- FENG 5.53
- 52 Week Low
- RNTX $1.04
- FENG $1.28
- 52 Week High
- RNTX $4.40
- FENG $3.49
- Technical
- Relative Strength Index (RSI)
- RNTX 45.62
- FENG 59.09
- Support Level
- RNTX $1.07
- FENG $2.51
- Resistance Level
- RNTX $1.25
- FENG $2.68
- Average True Range (ATR)
- RNTX 0.14
- FENG 0.22
- MACD
- RNTX -0.01
- FENG 0.01
- Stochastic Oscillator
- RNTX 21.33
- FENG 55.17
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About FENG Phoenix New Media Limited
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.